Clinical Trials
137 trialsOrigAMI-4
Janssen Research & Development, LLC
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
iMATRIX GLO
Hoffmann-La Roche
RAINFOL-01
Genmab
FONTANA
AstraZeneca
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Akeso
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
EPCOREâ„¢ NHL-2
Genmab
MRD
Imunon
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
Hangzhou DAC Biotechnology Co., Ltd.
MK-6070-003
Merck Sharp & Dohme LLC
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
TRIFOUR
Cantargia AB
MK-5909-003
Merck Sharp & Dohme LLC
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
MK-3475-01A
Merck Sharp & Dohme LLC
KRAScendo 170
Hoffmann-La Roche
Morpheus Lung
Hoffmann-La Roche
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
OVATION 2
Imunon
ALTAIR
AstraZeneca
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
HORIZON 2
Hoffmann-La Roche
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
EV-103
Astellas Pharma Inc
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
SYNERGY-101
Synthekine
Morpheus-panBC
Hoffmann-La Roche
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Akeso
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
PETRA
AstraZeneca
KEYNOTE-365
Merck Sharp & Dohme LLC
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Daiichi Sankyo
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited